The application of mathematical modelling to the design of bispecific monoclonal antibodies

mAbs

Volumn 8, Issue 3, 2016, Pages 585-592

  van Steeg, Tamara J ^a   Bergmann, Kirsten Riber ^a   Dimasi, Nazzareno ^b   Sachsenmeier, Kris F ^b   Agoram, Balaji ^b  

^a LAP P Consultants BV   (Netherlands)

^b MEDIMMUNE   (United States)

Author keywords

Affinity; avidity; binding; bispecific; limitation; mathematical; model; Monovalent; spatial

Indexed keywords

BISPECIFIC ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY;

ANTIBODY AFFINITY; ANTIBODY BLOOD LEVEL; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; CANCER THERAPY; COMPUTER SIMULATION; FLUORESCENCE ACTIVATED CELL SORTING; MATHEMATICAL MODEL; PROTEIN EXPRESSION; THERAPEUTIC INDEX; BIOLOGICAL MODEL; CHEMISTRY; IMMUNOLOGY; MOLECULAR MODEL;

ANTIBODIES, BISPECIFIC; COMPUTER SIMULATION; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR;

EID: 84961204065     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.1080/19420862.2016.1141160     Document Type: Article

References (28)

1. F.H.Groenendijk, R.Bernards. Drug resistance to targeted therapies: Déjà vu all over again. Mol Oncol 2014; 12:1-17; PMID:24910388; http://dx.doi.org/:10.1016/j.molonc.2014.05.004.
2. C.Holohan, S.Van Schaeybroeck, D.B.Longley, P.G.Johnston. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013; 13:714-26; PMID:24060863; http://dx.doi.org/10.1038/nrc3599
3. Y.Mazor, V.Oganesyan, C.Yang, A.Hansen, J.Wang, H.Liu, K.Sachsenmeier, M.Carlson, D.V.Gadre, M.J.Borrok, et al. Improving target cell specificity using a novel monovalent bispecific IgG design. MAbs 2015; 7:37-41 PMID:25621507; http://dx.doi.org/10.1080/19420862.2015.1007816.
4. R.Croasdale, K.Wartha, J.M.Schanzer, K.-P.Kuenkele, C.Ries, K.Mayer, C.Gassner, M.Wagner, N.Dimoudis, S.Herter, et al. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition. Arch Biochem Biophys 2012; 526:206-18; PMID:22464987; http://dx.doi.org/10.1016/j.abb.2012.03.016
5. J.Dong, A.Sereno, D.Aivazian, E.Langley, B.R.Miller, W.B.Snyder, E.Chan, M.Cantele, R.Morena, I.B.J.K.Joseph, et al. A stable IgG-like bispecific antibody targeting the epidermal growth factor receptor and the type I insulin-like growth factor receptor demonstrates superior anti-tumor activity. MAbs 2011; 3:273-88; PMID:21393993; http://dx.doi.org/10.4161/mabs.3.3.15188
6. J.M.Schanzer, K.Wartha, R.Croasdale, S.Moser, K.-P.Künkele, C.Ries, W.Scheuer, H.Duerr, S.Pompiati, J.Pollman, et al. A Novel Glycoengineered Bispecific Antibody Format for Targeted Inhibition of Epidermal Growth Factor Receptor (EGFR) and Insulin-like Growth Factor Receptor Type I (IGF-1R) Demonstrating Unique Molecular Properties. J Biol Chem 2014; 289:18693-706; PMID:24841203; http://dx.doi.org/10.1074/jbc.M113.528109
7. S.L.Emanuel, L.J.Engle, G.Chao, R.-R.Zhu, C.Cao, Z.Lin, A.P.Yamniuk, J.Hosbach, J.Brown, E.Fitzpatrick, et al. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor. MAbs 2011; 3:38-48; PMID:21099371; http://dx.doi.org/10.4161/mabs.3.1.14168
8. D.Lu, H.Zhang, H.Koo, J.Tonra, P.Balderes, M.Prewett, E.Corcoran, V.Mangalampalli, R.Bassi, D.Anselma, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280:19665-72; PMID:15757893; http://dx.doi.org/10.1074/jbc.M500815200
9. E.N.Kaufman, R.K.Jain. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res 1992; 52:4157-67; PMID:1638531
10. K.M.Müller, K.M.Arndt, A.Plückthun. Model and simulation of multivalent binding to fixed ligands. Anal Biochem 1998; 261:149-58; PMID:9716417; http://dx.doi.org/10.1006/abio.1998.2725
11. V.Doldán-Martelli, R.Guantes, D.G.Míguez. A mathematical model for the rational design of chimeric ligands in selective drug therapies. CPT pharmacometrics Syst Pharmacol 2013; 2:e26; PMID:23887616; http://dx.doi.org/10.1038/psp.2013.2
12. B.D.Harms, J.D.Kearns, S.Iadevaia, A.Lugovskoy. Understanding the role of cross-arm binding efficiency in the activity of monoclonal and multispecific therapeutic antibodies. Methods 2014; 65:95-104; PMID:23872324; http://dx.doi.org/10.1016/j.ymeth.2013.07.017
13. V.L.Chudasama, A.Zutshi, P.Singh, A.K.Abraham, D.E.Mager, J.M.Harrold. Simulations of site-specific target-mediated pharmacokinetic models for guiding the development of bispecific antibodies. J Pharmacokinet Pharmacodyn 2015; 42(1):1-18; PMID:25559227; http://dx.doi.org/10.1007/s10928-014-9401-1
14. B.D.Harms, J.D.Kearns, S.V.Su, N.Kohli, U.B.Nielsen, B.Schoeberl. Optimizing properties of antireceptor antibodies using kinetic computational models and experiments. Methods Enzymol 2012; 502:67-87; PMID:22208982; http://dx.doi.org/10.1016/B978-0-12-416039-2.00004-5
15. C.Arteaga. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003; 284:122-30; PMID:12648471; http://dx.doi.org/10.1016/S0014-4827(02)00104-0
16. A.A.Kortt, O.Dolezal, B.E.Power, P.J.Hudson. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 2001; 18:95-108; PMID:11566601; http://dx.doi.org/10.1016/S1389-0344(01)00090-9
17. B.Gorovits, C.Krinos-Fiorotti. Proposed mechanism of off-target toxicity for antibody–drug conjugates driven by mannose receptor uptake. Cancer Immunol Immunother 2012; 62:217-23; PMID:23223907; http://dx.doi.org/10.1007/s00262-012-1369-3
18. A.M.Gillespie, T.J.Broadhead, S.Y.Chan, J.Owen, A.P.Farnsworth, M.Sopwith, R.E.Coleman. Original article Phase I open study of the effects of ascending doses of the cytotoxic. Ann Oncol 2000; 11:735-41; PMID:10942064; http://dx.doi.org/10.1023/A:1008349300781
19. F.J.Giles, H.M.Kantarjian, S.M.Kornblau, D.A.Thomas, G.Garcia-Manero, T.A.Waddelow, C.L.David, A.T.Phan, D.E.Colburn, A.Rashid, et al. Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001; 92:406-13; PMID:11466696; http://dx.doi.org/10.1002/1097-0142(20010715)92:2%3c406::AID-CNCR1336%3e3.0.CO;2-U
20. M.Onda, M.Willingham, Q.C.Wang, R.J.Kreitman, Y.Tsutsumi, S.Nagata, I.Pastan. Inhibition of TNF- Produced by Kupffer Cells Protects Against the Nonspecific Liver Toxicity of Immunotoxin Anti-Tac(Fv)-PE38, LMB-2. J Immunol 2000; 165:7150-6; PMID:11120846; http://dx.doi.org/10.4049/jimmunol.165.12.7150
21. M.Onda, R.J.Kreitman, G.Vasmatzis, B.Lee, I.Pastan. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. J Immunol 1999; 163:6072-7; PMID:10570296
22. M.G.Batelli, L.Buonamici, L.Politio, A.Bolognesi, F.Stirpe. Hepatotoxicity of ricin, saporin or a saporin immunotoxin: xanthine oxidase activity in rat liver and blood serum. Virchows Arch 1996; 427:529-35; PMID:8624583
23. K.W.Mosure, J.Henderson a, L.J.Klunk, J.O.Knipe. Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248). Cancer Chemother Pharmacol 1997; 40:251-8; PMID:9219510; http://dx.doi.org/10.1007/s002800050655
24. Y.Cao, L.Lam. Bispecific antibody conjugates in therapeutics. 2003; 55:171-97; PMID:12564976
25. T.D.Chittenden, Y.Y.Setiady, P.U.Park, J.F.Ponte, L.Dong, A.Skaletskaya, C.N.Carrigan, A.A.Villaluz, J.Pinkas, R.J.Lutz, J.M.Lambert. IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway. Cancer Res 2013; 73:Abstract nr 5467; http://dx.doi.org/10.1158/1538-7445.AM2013-5467
26. R.A.Burrell, C.Swanton. Tumour heterogeneity and the evolution of polyclonal drug resistance. Mol Oncol 2014; 8(6):1095-111; PMID:25087573; http://dx.doi.org/10.1016/j.molonc.2014.06.005.
27. B.-F.Krippendorff, D.A.OyarzúnD a, W.Huisinga. Predicting the F(ab)-mediated effect of monoclonal antibodies in vivo by combining cell-level kinetic and pharmacokinetic modelling. J Pharmacokinet Pharmacodyn 2012; 39:125-39; PMID:22399130; http://dx.doi.org/10.1007/s10928-012-9243-7
28. D.Patel, X.Guo, S.Ng, M.Melchior, P.Balderes, D.Burtrum, K.Persaud, X.Luna, D.L.Ludwig, X.Kang. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies 2010; 19:89-99; PMID:21178280; http://dx.doi.org/10.3233/HAB-2010-0232.